Skip to main content
Open Access Publications from the University of California

Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML

  • Author(s): Cortes, JE
  • Tallman, MS
  • Schiller, GJ
  • Trone, D
  • Gammon, G
  • Goldberg, SL
  • Perl, AE
  • Marie, J-P
  • Martinelli, G
  • Kantarjian, HM
  • Levis, MJ
  • et al.
Main Content
Current View